Insider Buying: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Buys 73,649 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par purchased 73,649 shares of KalVista Pharmaceuticals stock in a transaction dated Friday, February 7th. The shares were acquired at an average cost of $9.29 per share, for a total transaction of $684,199.21. Following the completion of the transaction, the insider now owns 5,086,445 shares of the company’s stock, valued at approximately $47,253,074.05. This represents a 1.47 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 10th, Venrock Healthcare Capital Par bought 4,137 shares of KalVista Pharmaceuticals stock. The shares were acquired at an average price of $9.14 per share, for a total transaction of $37,812.18.
• On Monday, February 3rd, Venrock Healthcare Capital Par purchased 14,562 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average price of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par acquired 43,707 shares of KalVista Pharmaceuticals stock. The shares were bought at an average price of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Price Performance

NASDAQ:KALV traded up $0.08 during mid-day trading on Tuesday, hitting $9.27. The company’s stock had a trading volume of 239,790 shares, compared to its average volume of 293,951. The business’s fifty day moving average is $8.75 and its two-hundred day moving average is $10.58. The stock has a market cap of $458.12 million, a price-to-earnings ratio of -2.55 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.01. Analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on KALV shares. Bank of America started coverage on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price on the stock. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. JMP Securities started coverage on KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an “outperform” rating and a $19.00 price target on the stock. Finally, TD Cowen assumed coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price objective for the company. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, KalVista Pharmaceuticals has an average rating of “Buy” and a consensus target price of $23.80.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. State Street Corp boosted its position in KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock worth $14,725,000 after purchasing an additional 515,179 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new position in shares of KalVista Pharmaceuticals during the 4th quarter worth approximately $634,000. Vestal Point Capital LP lifted its position in shares of KalVista Pharmaceuticals by 73.9% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock valued at $46,320,000 after buying an additional 1,700,000 shares in the last quarter. Barclays PLC grew its stake in KalVista Pharmaceuticals by 418.5% in the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after acquiring an additional 54,257 shares during the period. Finally, Readystate Asset Management LP purchased a new stake in KalVista Pharmaceuticals in the 3rd quarter worth $2,084,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).